Table 2.
Characteristics of survey participants
| CHC patientsa N = 328 |
|
|---|---|
| Age (years), mean ± SD | 47.7 ± 14.4 |
| Female, n (%) | 168 (51.2) |
| Country/region, n (%) | |
| USA | 227 (69.2) |
| European countriesb | 101 (30.8) |
| Highest level of formal education, n (%) | |
| Completed 6–12 years of education | 103 (31.4) |
| Completed > 12 years of education | 225 (68.6) |
| Employment status, n (%) | |
| Employed | 176 (53.7) |
| Not working | 140 (42.7) |
| Student | 8 (2.4) |
| Declined to answer | 4 (1.2) |
| HCV genotype among patients reporting genotype (n = 206), n (%)c | |
| Genotype 1 | 74 (35.9) |
| Genotype 2 | 51 (24.8) |
| Genotype 3 | 57 (27.7) |
| Genotype 4 | 21 (10.2) |
| Genotype 5 | 3 (1.5) |
| Genotype 6 | 0 (0.0) |
| Time since HCV diagnosis, n (%) | |
| Within the last 1 year | 18 (5.5) |
| More than 1 year, but less than 3 years | 43 (13.1) |
| Between 3 and 5 years | 40 (12.2) |
| More than 5 years | 227 (69.2) |
| Time since HCV diagnosis (years), mean ± SD | 11.2 ± 7.2 |
| Treatment history, n (%) | |
| Treatment-naïve | 131 (39.9) |
| Treatment-experienced | 197 (60.1) |
| Told cured by doctor, n (%) | 163 (49.7) |
| Selected key chronic comorbidities, n (%) | |
| Anxiety/depression | 149 (45.4) |
| Cardiovascular disease (e.g., ischemic heart disease) | 29 (8.8) |
| Cirrhosis | 47 (14.3) |
| Diabetes/insulin resistance | 59 (18.0) |
| Fibrosis | 33 (10.1) |
| Gastroesophageal reflux disease | 77 (23.5) |
| Hepatitis B virus infection | 32 (9.8) |
| HIV infection/AIDS | 23 (7.0) |
| Kidney disease | 24 (7.3) |
| Liver cancer | 17 (5.2) |
| Liver transplant | 20 (6.1) |
| Injectable recreational drug use, n (%) | |
| Never used | 154 (47.0) |
| Former/current user | 162 (49.4) |
| Decline to answer | 12 (3.7) |
| Concurrent medications, n (%) | |
| Receiving PPIs | 59 (18.0) |
| Receiving statins | 67 (20.4) |
| Patient motivation level (by PAM-13), n (%) | |
| Level 1 (not yet believe patients have active/important role) | 27 (8.4) |
| Level 2 (lack confidence/knowledge to take action) | 34 (10.6) |
| Level 3 (beginning to take action) | 148 (46.0) |
| Level 4 (maintaining behavior over time) | 113 (35.1) |
HCV hepatitis C virus, HIV human immunodeficiency virus, AIDS acquired immunodeficiency syndrome, PPI proton pump inhibitor
aInclude patients from the USA and European countries
bUK, France, Germany, Spain, and Italy
cCounts for categorical variables may not sum to 328 because of missing data or patients declining to answer certain questions